Influence of alemtuzumab on the intestinal Paneth cells and microflora in macaques

Clinical Immunology

Volumn 136, Issue 3, 2010, Pages 375-386

  Li, Qiurong ^a,b   Zhang, Qiang ^a,b   Wang, Chenyang ^a   Tang, Chun ^a   Zhang, Yanmei ^a   Jiang, Shaojun ^a   Li, Ning ^a   Li, Jieshou ^a,b  

^a JINLING HOSPITAL   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Alemtuzumab; Defensin 5; Lysozyme; Microflora; Paneth cell

Indexed keywords

ALEMTUZUMAB; BETA DEFENSIN 5; GAMMA INTERFERON; INTERLEUKIN 10; LYSOZYME; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL GRANULE; CELL SECRETION; CONTROLLED STUDY; DISEASE ASSOCIATION; INTESTINE FLORA; LYMPHOCYTE DEPLETION; MACACA; MALE; NONHUMAN; PANETH CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE;

EID: 77955281353     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.05.004     Document Type: Article

References (49)

1. Ayabe T., Satchell D.P., Wilson C.L., Parks W.C., Selsted M.E., Ouellette A.J. Secretion of microbicidal-defensins by intestinal Paneth cells in response to bacteria. Nat. Immunol. 2000, 1:113-118.
2. Meyer-Hoffert U., Hornef M.W., Henriques-Normark B., Axelsson L.G., Midtvedt T., Pütsep K., Andersson M. Secreted enteric antimicrobial activity localizes to the mucus surface layer. Gut 2008, 57:764-771.
3. Vaishnava S., Behrendta C.L., Ismaila A.S., Eckmannb L., Hoopera L.V. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc. Natl. Acad. USA 2008, 105:20858-20863.
4. Wehkamp J., Salzman N.H., Porter E., Nuding S., Weichenthal M., Petras R.E., Shen B., Schaeffeler E., Schwab M., Linzmeier R., Feathers R.W., Chu H., Lima H., Fellermann K., Ganz T., Stange E.F., Bevins C.L. Reduced Paneth cell α-defensins in ileal Crohn's disease. Proc. Natl. Acad. USA 2005, 102:18129-18134.
5. Wehkamp J., Harder J., Weichenthal M., Schwab M., Schäffeler E., Schlee M., Herrlinger K.R., Stallmach A., Noack F., Fritz P., Schröder J.M., Bevins C.L., Fellermann K., Stange E.F. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004, 53:1658-1664.
6. Wehkamp J., Fellermann K., Stange E.F. Human defensins in Crohn's disease. Chem. Immunol. Allergy 2005, 86:42-54.
7. Elphick D., Liddell S., Mahida Y.R. Impaired luminal processing of human defensin-5 in Crohn's disease persistence in a complex with chymotrypsinogen and trypsin. Am. J. Pathol. 2008, 172:702-713.
8. Kelly P., Feakins R., Domizio P., Murphy J., Bevins C., Wilson J. Paneth cell granule depletion in the human small intestine under infective and nutritional stress. Clin. Exp. Immunol. 2004, 135:303-309.
9. Salzman N.H., Chou M.M., de Jong H., Liu L.D., Porter E.M., Paterson Y. Enteric salmonella infection inhibits Paneth cell antimicrobial peptide expression. Infect. Immun. 2003, 71:1109-1115.
10. Elphick D.A., Mahida Y.R. Paneth cells: their role in innate immunity and inflammatory disease. Gut 2005, 54:1802-1809.
11. Selsted M.E., Ouellette A.J. Mammalian defensins in the antimicrobial immune response. Nat. Immunol. 2005, 6:551-557.
12. Morris P.J., Russell N.K. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 2006, 81:1361-1367.
13. Bloom D.D., Hu H.Z., Fechne R.J.H., Knechtle S.J. T-lymphocyte alloresponses of Alemtuzumab-treated kidney transplant patients. Transplantation 2006, 81:81-87.
14. Garcia M., Weppler D., Mittal N., Nishida S., Kato T., Tzakis A., Ruiz P. Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation. Transplant. P. 2004, 36:323-324.
15. Shapiro R., Ellis D., Tan H.P., Moritz M.L., Basu A., Vats A.N., Kayler L.K., Erkan E., Mcfeaters C.G., James G., Grosso M.J., Zeevi A., Gray E.A., Marcos A., Starzl T.E. Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation. Am. J. Transplant. 2007, 7:2736-2738.
16. Stanglmaier M., Reis S., Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann. Hematol. 2004, 83:634-645.
17. Knechtle S.J., Pirsch J.D., Fechner H., Becker B.N., Friedl A., Colvin R.B., et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am. J. Transplant. 2003, 3:722-730.
18. Walsh R., Ortiz J., Foster P., Palma-Vargast J., Rosenblat S., Wright F. Fungal and mycobacterial infections after Campath (alemtuzumab) induction for renal transplantation. Transpl. Infect. Dis. 2008, 10:236-239.
19. Heider U., Fleissner C., Zavrski I., Jakob C., Dietzel T., Eucker J. Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection. Eur. J. Haematol. 2004, 72:64-66.
20. Li Q.R., Zhang Q., Wang C.Y., Li Y.X., Wu B., Liu X.X., Li N., Li J.S. Alteration of tight junctions in intestinal transplantation induced by Campath-1H. Clin. Immunol. 2009, 132:141-143.
21. Kamal M., Wakelin D., Ouellette A.J., Smith A., Podolsky D.K., Mahida Y.R. Mucosal T cells regulate Paneth and intermediate cell numbers in the small intestine of T. spiralis-infected mice. Clin. Exp. Immunol. 2001, 126:117-125.
22. Ouellette A.J. Mucosal immunity and inflammation IV. Paneth cell antimicrobial peptides and the biology of the mucosal barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 1999, 277:G257-G261.
23. Ishikawa N., Wakelin D., Mahida Y.R. Role of T helper 2 cells in intestinal goblet cell hyperplasia in mice infected with Trichinella spiralis. Gastroenterology 1999, 113:542-559.
24. Loisel S., Ohresser M., Pallardy M., Daydé D., Berthou C., Cartron G., Watier H. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit. Rev. Oncol. Hemat. 2007, 62:34-42.
25. Montufar-Solis D., Klein J.R. An improved method for isolating intraepithelial lymphocytes (IELs) from the murine small intestine with consistently high purity. J. Immunol. Meth. 2006, 308:251-254.
26. Poxton I.R., Brown R., Sawyerr A., Ferguson A. Mucosa-associated bacterial flora of the human colon. J. Med. Microbiol. 1997, 46:85-91.
27. Jernberg C., Sullivan A., Edlund C., Jansson J.K. Monitoring of antibiotic-induced alterations in the human intestinal microflora and detection of probiotic strains by use of terminal restriction fragment length polymorphism. Appl. Environ. Microb. 2005, 71:501-506.
28. Zoetendal E.G., von Wright A., Vilpponen-Salmela T., Ben-Amor K., Akkermans A.D.L., de Vos W.M. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl. Environ. Microb. 2002, 68:3401-3407.
29. Favier C.F., Vaughan E.E., de Vosk W.M., Akkermans A.D.L. Molecular monitoring of succession of bacterial communities in human neonates. Appl. Environl. Microb. 2002, 68:219-226.
30. Kato T., Tzakis A.G., Selvaggi G., Gaynor J.J., David A.I., Bussotti A., Moon J.I., Ueno T., DeFaria W., Santiago S., Levi D.M., Nishida S., Velasco M.L., McLaughlin G., Hernandez E., Thompson J.F., Cantwell P., Holliday N., Livingstone A.S., Ruiz P. Intestinal and multivisceral transplantation in children. Ann. Surg. 2006, 243:756-766.
31. Lauro A., Amaduzzi A., Dazzi A., Ercolani G., Zanfi C., Golfieri L., Grazi G.L., Vivarelli M., Cescon M., Varotti G., Del Gaudio M., Ravaioli M., Siniscalchi A., Faenza S., D'Errico A., Di Simone M., Pironi L., Pinna A.D. Daclizumab and alemtuzumab as induction reagents in adult intestinal and multivisceral transplantation: a comparison of two different regimens on 29 recipients during the early postoperative period. Dig. Liver Dis. 2007, 39:253-256.
32. Tzakis A.G., Kato T., Levi D.M., DeFaria W., Selvaggi G., Weppler D., Nishida S., Moon J., Madariaga J.R., David A.I., Gaynor J.J., Thompson J., Hernandez E., Martinez E., Cantwell G.P., Augenstein J.S., Gyamfi A., Pretto E.A., Dowdy L., Tryphonopoulos M., Ruiz P. 100 multivisceral transplants at a single center. Ann. Surg. 2005, 242:480-493.
33. Kaufman D.B., Leventhal J.R., Axelrod D., Gallon L.G., Parker M.A., Stuart F.P. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction-long-tem results. Am. J. Transplant. 2005, 5:2539-2548.
34. Tzakis A.G., Tryphonopoulos P., Kato T., Nishida S., Levi D.M., Madariaga J.R., Gaynor J.J., De Faria W., Regev A., Esquenazi V., Weppler D., Ruiz P., Miller J. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 2004, 77:1209-1214.
35. Munoz-Price L.S., Slifkin M., Ruthazer R., Poutsiaka D.D., Hadley S., Freeman R., Rohrer R., Angelis M., Cooper J., Fairchild R., Barefoot L., Bloom J., Fitzmaurice S., Snydman D.R. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin. Infect. Dis. 2004, 39:1293-1299.
36. Paya C.V., Wiesner R.H., Hermans P.E., Larson-Keller J.J., Ilstrup D.M., Krom R.A., Rettke S., Smith T.F. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J. Hepatol. 1993, 18:185-195.
37. Nizet V., Ohtake T., Lauth X., Trowbridge J., Rudisill J., Dorschner R.A., Pestoniamasp V., Piraino J., Huttner K., Gallo R.L. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001, 414:454-457.
38. Ong P.Y., Ohtake T., Brandt C., Strickland I., Boguniewicz M., Ganz T., Gallo R.L., Leung D.Y.M. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 2002, 347:1151-1160.
39. Kamal M., Wakelin D., Mahida Y. Mucosal responses to infection with Trichinella spiralis in mice. Parasite 2001, 8:S110-S113.
40. Alnadjim Z., Cohn S.M., Ayabe T., Biafora S., Ouellette A.J., Barrett T.A. T cell activation instructs epithelial lineage development by inducing Paneth cell expansion and cryptdin production in intestinal crypts. Gastroenterology 2001, 120:A21.
41. Yang H., Antony P.A., Wildhaber B.E., Teitelbaum D.H. Intestinal intraepithelial lymphocyte γδ-T cell-derived keratinocyte growth factor modulates epithelial growth in the mouse. J. Immunol. 2004, 172:4151-4158.
42. Yang H., Sun X.Y., Haxhija E., Teitelbaum D.H. Intestinal epithelial cell-derived interleukin-7: A mechanism for the alteration of intraepithelial lymphocytes in a mouse model of total parenteral nutrition. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292:G84-G91.
43. Sun X., Yang H., Nose K., Nose S., Haxhija E.Q., Koga H., Feng Y., Teitelbaum D.H. Decline in intestinal mucosal IL-10 expression and decreased intestinal barrier function in a mouse model of total parenteral nutrition. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294:G139-G147.
44. Yang H., Gumucio D.L., Teitelbaum D.H. Intestinal specific over-expression of interleukin-7 attenuates the alternation of intestinal intraepithelial lymphocytes after TPN administration. Ann. Surg. 2008, 248:849-856.
45. Taylor C.T., Murphy A., Kelleher D., Baird A.W. Changes in barrier function of a model intestinal epithelium by intraepithelial lymphocytes require new protein synthesis by epithelial cells. Gut 1997, 40:634-640.
46. Shibahara T., Miyazaki K., Sato D., Matsui H., Yanaka A., Nakahara A., Tanaka N. Alteration of intestinal epithelial function by intraepithelial lymphocyte homing. J. Gastroenterol. 2005, 40:878-886.
47. + lymphocytes maintain the integrity of intestinal epithelial tight junctions in response to infection. Gastroenterology 2006, 131:818-829.
48. Bry L., Falk P., Huttner K., Ouellette A., Midtvedt T., Gordon J.I. Paneth cell differentiation in the developing intestine of normal and transgenic mice. Proc. Natd. Acad. Sci. USA 1994, 91:10335-10339.
49. Cunliffe R.N. Alpha-Defensins in the gastrointestinal tract. Mol. Immunol. 2003, 40:463-467.